Edition:
United States

Tandem Diabetes Care Inc (TNDM.OQ)

TNDM.OQ on NASDAQ Stock Exchange Global Market

1.25USD
24 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.25
Open
$1.25
Day's High
$1.25
Day's Low
$1.17
Volume
402,943
Avg. Vol
93,633
52-wk High
$11.28
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

Tandem Diabetes reports public offering of 18 mln shares
Thursday, 23 Mar 2017 08:30am EDT 

Tandem Diabetes Care Inc : Tandem Diabetes care announces pricing of underwritten public offering of common stock .Says public offering of 18.0 million common shares priced at $1.25 per share.  Full Article

Tandem Diabetes Care prices common stock offering of 18 mln shares
Thursday, 23 Mar 2017 06:47am EDT 

Tandem Diabetes Care Inc :Tandem Diabetes Care Inc - prices common stock offering of 18 million shares at $1.25 per share.  Full Article

Tandem Diabetes Care says offering 18 mln shares of common stock
Monday, 20 Mar 2017 09:48am EDT 

Tandem Diabetes Care Inc : Tandem Diabetes Care Inc says offering 18 million shares of common stock, par value $0.001 per share - SEC filing Further company coverage: [TNDM.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Tandem Diabetes Care files for common stock offering of up to $57.5 mln
Wednesday, 8 Mar 2017 04:25pm EST 

Tandem Diabetes Care Inc :Tandem Diabetes Care files for common stock offering of up to $57.5 million - SEC filing.  Full Article

Tandem Diabetes Care qtrly loss per share $0.48
Wednesday, 8 Mar 2017 04:05pm EST 

Tandem Diabetes Care Inc : Tandem Diabetes Care reports 2016 financial results . Q4 sales fell 1 percent to $28.9 million . Sees FY 2017 non-GAAP sales $100 million to $107 million . Q4 revenue view $22.7 million -- Thomson Reuters I/B/E/S . Pump shipments grew 9 percent to 16,938 for year ended December 31, 2016 compared to 15,483 pumps shipped in 2015 . Non-GAAP sales decreased 15 percent to $24.8 million in Q4 of 2016 . Non-GAAP sales for Q1 2017 are estimated to be 15 percent of annual sales . Qtrly loss per share $0.48 . Q4 earnings per share view $-0.65, revenue view $22.7 million -- Thomson Reuters I/B/E/S .FY2017 revenue view $103.7 million -- Thomson Reuters I/B/E/S.  Full Article

Tandem Diabetes Care now taking orders for t:slim X2 Insulin Pump
Tuesday, 4 Oct 2016 08:30am EDT 

Tandem Diabetes Care Inc : Tandem Diabetes Care now taking orders for next-generation t:slim X2 Insulin Pump .Shipments of t:slim X2 Pump are expected to begin late October 2016.  Full Article

Tandem Diabetes Care Q2 sales $23 million
Thursday, 28 Jul 2016 04:05pm EDT 

Tandem Diabetes Care Inc : Non-Gaap operating margin is estimated to be in range of negative 52 percent to negative 62 percent for FY . As of June 30, 2016, company had $56.3 million in cash, cash equivalents and short-term investments . Tandem diabetes care reports second quarter 2016 financial results, updates 2016 guidance and announces new T:SLIM X2(TM) insulin pump and associated technology upgrade program . Q2 sales $23 million versus I/B/E/S view $23.1 million .Non-Gaap sales are now estimated to be in range of $105 million to $110 million for FY.  Full Article

Tandem Diabetes says announces expanded pediatric indication of t:slim insulin pump
Tuesday, 26 Jul 2016 08:15am EDT 

Tandem Diabetes Care Inc : Fda clearance of an expanded pediatric indication for t:slim insulin pump .Expanded pediatric indication of t:slim insulin pump for ages 6 and older.  Full Article

Tandem Diabetes Care, TypeZero Technologies announce license agreement
Thursday, 21 Jul 2016 08:15am EDT 

Tandem Diabetes Care Inc : Says financial details of agreement have not been disclosed . Terms of license agreement include a worldwide, non-exclusive license for use of Typezero's AP technology in future tandem products . Tandem Diabetes Care and Typezero Technologies announce license agreement to accelerate development and commercialization of closed-loop artificial pancreas system . Agreement also provides tandem access to Typezero's future AP innovations over next five years .Anticipate research version of tandem's T:SLIM insulin pump will be used alongside Typezero's AP Technology in IDCL trial.  Full Article

Tandem Diabetes says got FDA clearance of remote software update tool for insulin pumps
Thursday, 14 Jul 2016 08:15am EDT 

Tandem Diabetes Care Inc : Tandem Diabetes Care announces FDA clearance of remote software update tool for insulin pumps . Intends to roll out Tandem device updater first to early t:slim pump users throughout summer in a series of test groups .Tandem Diabetes says plans expanded launch for Tandem device later this year.  Full Article

More From Around the Web

BRIEF-Tandem Diabetes reports public offering of 18 mln shares

* Tandem Diabetes care announces pricing of underwritten public offering of common stock